GSK

GSK
D

GSK

Arincen73/100B

GSK return on equity (ROE)

GSK's return on equity is 23.49%: net income of 4.43B GBP over the last twelve months on shareholders' equity of 18.88B GBP.

Today
23.49%
Average, 5 years
29.93%
Low, 5 years
19.63%
High, 5 years
45.03%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 4.43B ÷ 18.88B = 23.49%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is GSK's return on equity so high?

Net margin
17.5%
profit on each dollar of sales
Asset turnover
0.54×
sales on each dollar of assets
Equity multiplier
3.73×
assets on each dollar of equity
Return on equity
35.0%
FY2025
  • FY202517.5% × 0.54 × 3.73 = 35.0%
  • FY20248.2% × 0.53 × 4.35 = 18.8%
  • FY202316.2% × 0.40 × 4.42 = 29.0%
  • FY202251.0% × 0.49 × 5.68 = 141.1%
  • FY202117.8% × 0.23 × 5.25 = 21.5%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today23.49%4.43B18.88B
FY202531 Dec 202534.20%5.59B16.35B
FY202431 Dec 202421.59%2.95B13.67B
FY202331 Dec 202336.00%6.13B17.01B
FY202231 Dec 202251.85%5.49B10.60B
FY202131 Dec 202117.24%3.52B20.39B
FY202031 Dec 202025.59%5.10B19.94B
FY201931 Dec 201934.87%5.27B15.11B
FY201831 Dec 2018107.01%4.05B3.78B
FY201731 Dec 2017—2.17B-68.00M
FY201631 Dec 201694.48%1.06B1.12B
FY201531 Dec 2015163.71%8.37B5.11B
FY201431 Dec 201466.41%2.83B4.26B
FY201331 Dec 201380.43%5.63B7.00B
FY201231 Dec 201281.65%4.74B5.81B
FY201131 Dec 201167.95%5.46B8.03B
FY201031 Dec 201020.85%1.85B8.89B
FY200931 Dec 200956.66%5.67B10.01B
FY200831 Dec 200859.41%4.71B7.93B
FY200731 Dec 200779.07%7.59B9.60B
FY200631 Dec 200683.19%7.81B9.39B
FY200531 Dec 200594.02%6.87B7.31B
FY200431 Dec 2004100.56%5.76B5.72B
FY200331 Dec 200382.70%6.38B7.71B
FY200231 Dec 200284.35%5.55B6.58B
FY200131 Dec 200162.98%4.74B7.53B
FY200031 Dec 200061.33%4.73B7.71B
FY199931 Dec 199983.55%2.63B3.14B
FY199831 Dec 199899.30%2.68B2.70B
FY199731 Dec 1997153.12%2.82B1.84B
FY199631 Dec 1996255.67%3.13B1.23B
FY199531 Dec 19952,617.58%2.38B91.00M
FY199430 Jun 1995253.19%1.04B410.48M
FY199330 Jun 199425.85%1.30B5.03B
FY199230 Jun 199326.55%1.21B4.55B
FY199130 Jun 199228.92%1.03B3.57B
FY199030 Jun 199127.46%881.00M3.21B
FY198930 Jun 199029.54%807.00M2.73B
FY198830 Jun 198930.03%688.00M2.29B
FY198730 Jun 198832.57%581.00M1.78B
FY198630 Jun 198735.17%510.00M1.45B
FY198530 Jun 198636.70%400.00M1.09B

Figures in GBP. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about GSK's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.